Publications by authors named "Thomas Weller"

Claim this Profile
A
Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
Andrew R Kompa, Jiayu Lu, Thomas J Weller, Darren J Kelly, Henry Krum

Int J Cardiol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electron Solvation and the Unique Liquid Structure of a Mixed-Amine Expanded Metal: The Saturated Li-NH -MeNH System.
Andrew G Seel, Helen Swan, Daniel T Bowron, Jonathan C Wasse, Thomas Weller

Angew Chem Int Ed Engl· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulators of Glucose Metabolism in CD4 and CD8 T Cells.
Clovis S Palmer, Tabinda Hussain, Gabriel Duette, Thomas J Weller, Matias Ostrowski

Int Rev Immunol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.
Amélie Le Bihan, Ruben de Kanter, Iñigo Angulo-Barturen, Christoph Binkert, Christoph Boss, Thomas Weller

PLoS Med· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action.
Christoph Boss, Hamed Aissaoui, Nathalie Amaral, Aude Bauer, Stephanie Bazire, Thomas Weller

ChemMedChem· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel S1P1 receptor agonists - Part 5: From amino-to alkoxy-pyridines.
Martin H Bolli, Cyrille Lescop, Magdalena Birker, Ruben de Kanter, Patrick Hess, Thomas Weller

Eur J Med Chem· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel S1P1 receptor agonists - Part 4: Alkylaminomethyl substituted aryl head groups.
Cyrille Lescop, Claus Müller, Boris Mathys, Magdalena Birker, Ruben de Kanter, Thomas Weller

Eur J Med Chem· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel S1P(1) receptor agonists--part 3: from thiophenes to pyridines.
Martin H Bolli, Stefan Abele, Magdalena Birker, Roberto Bravo, Daniel Bur, Thomas Weller

J Med Chem· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel S1P1 receptor agonists--part 1: From pyrazoles to thiophenes.
Martin H Bolli, Claus Müller, Boris Mathys, Stefan Abele, Magdalena Birker, Thomas Weller

J Med Chem· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2.
Thierry Sifferlen, Ralf Koberstein, Emmanuelle Cottreel, Amandine Boller, Thomas Weller

Bioorg Med Chem Lett· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1.
Thierry Sifferlen, Ralf Koberstein, Emmanuelle Cottreel, Amandine Boller, Thomas Weller

Bioorg Med Chem Lett· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Martin H Bolli, Christoph Boss, Christoph Binkert, Stephan Buchmann, Daniel Bur, Thomas Weller

J Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.
Martin H Bolli, Stefan Abele, Christoph Binkert, Roberto Bravo, Stephan Buchmann, Thomas Weller

J Med Chem· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists.
Thierry Sifferlen, Christoph Boss, Emmanuelle Cottreel, Ralf Koberstein, Markus Gude, Thomas Weller

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New classes of potent and bioavailable human renin inhibitors.
L'ubos Remen, Olivier Bezençon, Sylvia Richard-Bildstein, Daniel Bur, Lars Prade, Thomas Weller

Bioorg Med Chem Lett· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
Olivier Bezençon, Daniel Bur, Thomas Weller, Sylvia Richard-Bildstein, Lubos Remen

J Med Chem· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
Marc Iglarz, Christoph Binkert, Keith Morrison, Walter Fischli, John Gatfield, Thomas Weller

J Pharmacol Exp Ther· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Promotion of sleep by targeting the orexin system in rats, dogs and humans.
Catherine Brisbare-Roch, Jasper Dingemanse, Ralf Koberstein, Petra Hoever, Hamed Aissaoui, Thomas Weller

Nat Med· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bulk evidence for single-Gap s-wave superconductivity in the intercalated graphite superconductor C6Yb.
Mike Sutherland, Nicolas Doiron-Leyraud, Louis Taillefer, Thomas Weller, Mark Ellerby

Phys Rev Lett· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achiral, cheap, and potent inhibitors of Plasmepsins I, II, and IV.
Christoph Boss, Olivier Corminboeuf, Corinna Grisostomi, Solange Meyer, Andrew F Jones, Thomas Weller

ChemMedChem· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intradermal vaccination against influenza.
Thomas H Weller

N Engl J Med· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
Martine Clozel, Christoph Binkert, Magdalena Birker-Robaczewska, Céline Boukhadra, Shuang-Shuang Ding, Thomas Weller

J Pharmacol Exp Ther· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.
Martin H Bolli, Judith Marfurt, Corinna Grisostomi, Christoph Boss, Christoph Binkert, Thomas Weller

J Med Chem· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bis-sulfonamides as endothelin receptor antagonists.
Christoph Boss, Martin H Bolli, Thomas Weller, Walter Fischli, Martine Clozel

Bioorg Med Chem Lett· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.
Martin H Bolli, Christoph Boss, Martine Clozel, Walter Fischli, Patrick Hess, Thomas Weller

Bioorg Med Chem Lett· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis